Background & Objectives: Regarding the high prevalence of hyperlipidemia in the world especially in Iran, finding suitable and effective treatment seems justified. Metronidazole is the only drug that is used as an antiparasital and antiprotozoal agent. Researchers have found that oral dose of 750 mg/day has a suitable absorption, is widely distributed in the tissues and reaches to a blood level of 4-6 mg/ml. Despite its suitable efficiency, a few clinical trial have been conducted in this regard. This study was designed as such to examine the effect of metronidazole on lowering blood lipids. Methods: The present research was performed as a clinical trial without control, on 50 patients. All the patients filled out a special form (to show...
The study was aimed to evaluate Simvastatin and Fluvastatin effects on patients with hypercholestero...
Purpose: To evaluate the distribution of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinas...
Saroglitazar is a dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemi...
Background: Many studies have reported the effect of metronidazole on reducing blood lipids in diffe...
Metronidazole, a synthetic derivative of the nitroimidazole class is a known antibacterial and antip...
Introduction : Notable lipid abnormalities in DM include elevated LDL-C which have been reported to ...
Introduction:Hyperlipidaemia is an abnormally elevated levels of any or all lipids in the blood. A s...
Purpose: To evaluate the ability of the new food supplement, Body Lipid (BL), containing red yeast r...
Rationale & Objective: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor aliro...
Background: the use of statin to lower blood cholesterol is often associated with bothersome adverse...
Contains fulltext : 50254.pdf (publisher's version ) (Closed access)OBJECTIVES: Fa...
PURPOSE: To evaluate the distribution of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinas...
Introduction: We assessed the effects on serum lipids and colonic fermentation of two antibiotics, ...
Objectives: To study the effect of cholesterol lowering agents on lipid profile in obese patients. B...
Background: Type 2 diabetes mellitus (T2DM) is one of the most common non-communicable diseases asso...
The study was aimed to evaluate Simvastatin and Fluvastatin effects on patients with hypercholestero...
Purpose: To evaluate the distribution of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinas...
Saroglitazar is a dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemi...
Background: Many studies have reported the effect of metronidazole on reducing blood lipids in diffe...
Metronidazole, a synthetic derivative of the nitroimidazole class is a known antibacterial and antip...
Introduction : Notable lipid abnormalities in DM include elevated LDL-C which have been reported to ...
Introduction:Hyperlipidaemia is an abnormally elevated levels of any or all lipids in the blood. A s...
Purpose: To evaluate the ability of the new food supplement, Body Lipid (BL), containing red yeast r...
Rationale & Objective: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor aliro...
Background: the use of statin to lower blood cholesterol is often associated with bothersome adverse...
Contains fulltext : 50254.pdf (publisher's version ) (Closed access)OBJECTIVES: Fa...
PURPOSE: To evaluate the distribution of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinas...
Introduction: We assessed the effects on serum lipids and colonic fermentation of two antibiotics, ...
Objectives: To study the effect of cholesterol lowering agents on lipid profile in obese patients. B...
Background: Type 2 diabetes mellitus (T2DM) is one of the most common non-communicable diseases asso...
The study was aimed to evaluate Simvastatin and Fluvastatin effects on patients with hypercholestero...
Purpose: To evaluate the distribution of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinas...
Saroglitazar is a dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemi...